“We have developed a drug study protocol with researchers at the clinic. We add the carrier peptide LSTA1 to the standard treatment of adult glioblastoma patients with temozolomide. The aim of the study is to evaluate the safety and primary efficacy of the treatment in the setting of the initial phase of the study,” said study lead researcher Dr. Lenne-Triin Kõrgvee, senior physician-teacher at the clinic.
The plan is to include 30 glioblastoma patients from three centers and two countries in the study within one year: in addition to the Northern Estonia Regional Hospital, the study center is also the East Riga Clinical University School Hospital. The main researchers at the regional hospital are Dr. Kersti Oselin and Prof. Guntis Karelis in Latvia.
Developing an academic clinical drug research protocol and obtaining all the necessary pan-European approvals requires a very strong and well-functioning research team, which exists right in the university hospital.
Dr. Katrin Kaarna, Head of the Clinical Research Center of the Clinic’s Research and Development Service, who provided important support in the various stages of the study, underlined that all intermediate studies must be registered in the European Medicines Information System. clinical research (CTIS), so studies have the same standard and procedure across Europe. “However, an internationally accepted study also requires real-time transmission of the pseudonymized study data to the pharmaceutical company and continuous clinical monitoring of the study, so there is still important work to be done with the conduct of the study,” said Dr. Kaarna.
“I believe that the clinic has the complete capacity to initiate and conduct early-stage research, as evidenced by our research team of doctors, pharmacists and nurses, who have been strongly supported by the clinical research center team led by Dr. Kaarna “The doctoral student Dr. Johannes Pärtel Truusalu, an irreplaceable member of the research group, deserves a separate mention. My heartfelt thanks go to all the colleagues who participated in the preparation of the study with enthusiasm, care and attention,” said Dr. Kõrgvee.
In the clinic, in addition to Dr. Kõrgvee, senior pharmacists Jana Lass and Marika Saar also participate in the study, who also coordinate the guarantee of drug safety and the necessary reporting. The practice oncologists are Dr. Sandra Kase and Dr. Madis Joonsalu, and the coordinator is practice nurse Kristi Saar.
Dr. Kõrgvee highlighted the future prospect: “If we can carry out the study according to plan, and especially if we can describe the safety and efficacy indications of the addition of the carrier peptide, this will be an important development in the treatment of patients affected by glioblastoma and in improving the quality of life.”
On the same topic
2024-01-10 09:31:51
estonian-researchers-are-looking-for-an-answer-to-the-question-of-whether-the-carrier-peptide-makes-brain-tumor-treatment-more-effective